Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12292918 | 0.86 | TSHR (0.39) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL7876608 | 0.82 | TSHR (0.46) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL7079859 | 0.82 | TSHR (0.44) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL17085515 | 0.82 | TSHR (0.44) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL19838618 | 0.80 | TSHR (0.44) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL28660114 | 0.80 | TSHR (0.44) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL3237384 | 0.80 | TSHR (0.44) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL472962 | 0.80 | TSHR (0.44) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL23188208 | 0.78 | TSHR (0.43) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL21450961 | 0.78 | TSHR (0.43) | TSHRTP53CYP3A4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282548-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM | FUJIFILM CORPORATION (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120148957-A1 | PATTERN FORMING METHOD, CHEMICAL AMPLIFICATION RESIST COMPOSITION AND RESIST FILM | FUJIFILM CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282548-A1 | PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION AND RESIST FILM | RAD51, RER1, RXRA | TSHR 2059/4885TP53 1856/4885CYP3A4 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.